Upregulation of PCAT1, PCAT2, and PCAT3 LncRNAs in cervical cancer patients and their diagnostic value
Abstract Objective Cervical cancer is one of the most common cancers among women. Despite advances in vaccination and screening, barriers to early detection and effective treatment remain. lncRNAs play an important role in cancer progression and therapeutic responses. New lncRNAs such as PCAT1, PCAT...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | BMC Research Notes |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13104-025-07401-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Abstract Objective Cervical cancer is one of the most common cancers among women. Despite advances in vaccination and screening, barriers to early detection and effective treatment remain. lncRNAs play an important role in cancer progression and therapeutic responses. New lncRNAs such as PCAT1, PCAT2, and PCAT3 have shown oncogenic activities in multiple cancers, but their role in cervical cancer is not understood. This study investigated the expression patterns of PCAT1, PCAT2, and PCAT3 in cervical cancer to evaluate their use as diagnostic markers and therapeutic targets. Results The expression level of PCAT1, PCAT2, and PCAT3 was significantly (P value < 0.05) higher in tumor tissues.ROC analysis showed a moderate diagnostic biomarker value for PCAT1 (AUC 0.79, sensitivity 79%, specificity 69%). Spearman’s analysis showed a positive correlation between PCAT1-PCAT2 and PCAT1-PCAT3. PCAT1, PCAT2, and PCAT3 lncRNAs significantly increase in cervical cancerous tissues and may play a role as novel oncogenes. Their use as clinical diagnostic markers requires further studies. |
|---|---|
| ISSN: | 1756-0500 |